Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 14/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 14/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 14/20 | 0.59 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096158 | 1.00 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11ITGB1 | |
| SCHEMBL6095477 | 0.91 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL6095469 | 0.91 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL6098328 | 0.90 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6098325 | 0.90 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6094992 | 0.84 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL6095001 | 0.84 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11AVPR2 | |
| SCHEMBL6097404 | 0.84 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6097395 | 0.84 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6095263 | 0.84 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | claimed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | claimed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | IL1B, IL1A, TNF | MAPK14 1972/4885MAPK13 2918/4885MAPK12 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.